Volume 22 Issue 7
Jul.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(7): 1142-1145
SHANG Yumeng, KE Xiquan, CHU Zhengyang, FANG Chuanfa, HU Dongli, ZHANG Chengbin. Observation on the effect of Vonoprazan-based dual therapy in radical treatment of Helicobacter pylori[J]. Chinese Journal of General Practice, 2024, 22(7): 1142-1145. doi: 10.16766/j.cnki.issn.1674-4152.003585
Citation: SHANG Yumeng, KE Xiquan, CHU Zhengyang, FANG Chuanfa, HU Dongli, ZHANG Chengbin. Observation on the effect of Vonoprazan-based dual therapy in radical treatment of Helicobacter pylori[J]. Chinese Journal of General Practice, 2024, 22(7): 1142-1145. doi: 10.16766/j.cnki.issn.1674-4152.003585
shu

Observation on the effect of Vonoprazan-based dual therapy in radical treatment of Helicobacter pylori

doi: 10.16766/j.cnki.issn.1674-4152.003585
  • 1.

    Department of Gastroenterology, the Second Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233000, China

Funds:

 2022a05020022

  • Received Date: 2023-11-27
    Available Online: 2024-09-05
    Abstract
  •   Objective  To observe the clinical efficacy, safety, compliance, and vonoprazan fumarate tablet (VPZ) combined with amoxicillin capsule for 10 days in the treatment of Helicobacter pylori (Hp) infection.  Methods  A total of 150 Hp infected patients diagnosed in the Second Affiliated Hospital of Bengbu Medical University from October 2021 to February 2023 were randomly divided into a control group (75 cases) and an experimental group (75 cases) by random number table method. The control group was given esomeprazole magnesium enteric-coated tablets combined with amoxicillin capsules, metronidazole tablets, and colloidal bismuth pectin capsules. The experimental group was given the vonoprazan fumarate tablet and amoxicillin capsule. Both groups were treated for 10 days. Hp eradication rate, incidence of adverse reactions, compliance, and cost-effectiveness ratio were compared between the two groups.  Results  There were 5 cases of shedding in the experimental group and 7 cases in the control group, a total of 12 cases of shedding, 70 cases in the experimental group and 68 cases in the control group. According to the protocol (PP) analysis, the eradication rates of Hp in the experimental group and control group were 91.43% (64/70) and 83.82% (57/68), respectively, with no statistical significance (P=0.174). According to intention-to-treat (ITT) analysis, the eradication rates of the experimental group and control group were 85.33% (64/75) and 76.00% (57/75), respectively, with no statistical significance (P=0.148). The incidence of adverse reactions in the experimental group and the control group was 4.29% (3/70) and 14.71% (10/68), respectively, and the difference was statistically significant (P < 0.05). The compliance of the experimental group and the control group was 97.14% (68/70) and 88.24% (60/68), respectively, with no statistical significance (P=0.091). The cost-effectiveness ratio of the experimental group and the control group were 2.22 and 3.64, respectively.  Conclusion  Compared with esomeprazole magnesium enteric-coated tablet combined with two antibiotics and bismuth, Vonolazan fumarate tablet combined with one antibiotic in the radical treatment of Hp infection patients has the same clinical efficacy, high safety and benefit, and good compliance, which is worthy of clinical promotion.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    彭若琳, 张振玉. 幽门螺杆菌耐药分子生物学检测的研究进展[J]. 胃肠病学和肝病学杂志, 2023, 32(12): 1394-1398. doi: 10.3969/j.issn.1006-5709.2023.12.015

    PENG R L, ZHANG Z Y. Advances on molecular biological detection of Helicobacter pylori resistance[J]. Chinese Journal of Gastroenterology and Hepatology, 2023, 32(12): 1394-1398. doi: 10.3969/j.issn.1006-5709.2023.12.015
    [2]
    高水永. 奥美拉唑镁肠溶片联合复方枸橼酸铋钾甲硝唑胶囊治疗幽门螺杆菌感染相关消化性溃疡的疗效观察[J]. 中国医药指南, 2023, 21(31): 26-29. https://www.cnki.com.cn/Article/CJFDTOTAL-YYXK202331007.htm

    GAO S Y. Efficacy of omeprazole magnesium enteric-coated tablets combined with compound bismuth potassium citrate and metronidazole capsules in the treatment of peptic ulcer associated with Helicobacter pylori infection[J]. Guide of China Medicine, 2023, 21(31): 26-29. https://www.cnki.com.cn/Article/CJFDTOTAL-YYXK202331007.htm
    [3]
    赵书鹏, 翟蕾蕾, 王海昆, 等. 双联每日4次口服疗法和铋剂四联疗法治疗幽门螺杆菌感染疗效Meta分析[J]. 胃肠病学和肝病学杂志, 2023, 32(11): 1242-1248. doi: 10.3969/j.issn.1006-5709.2023.11.009

    ZHAO S P, ZHAI L L, WANG H K, et al. Efficacy of dual oral therapy and bismuth quadruple therapy in the treatment of Helicobacter pylori infection: a Meta-analysis[J]. Chinese Journal of Gastroenterology and Hepatology, 2023, 32(11): 1242-1248. doi: 10.3969/j.issn.1006-5709.2023.11.009
    [4]
    杜梅玲, 楚艳, 张自强, 等. 萎缩性与非萎缩性胃炎患者之间幽门螺杆菌根除率的差异性研究[J]. 中华全科医学, 2023, 21(6): 920-923, 957. doi: 10.16766/j.cnki.issn.1674-4152.003015

    DU M L, CHU Y, ZHANG Z Q, et al. Difference of Helicobacter pylori eradication rate between patients with atrophic gastritis and non-atrophic gastritis[J]. Chinese Journal of General Practice, 2023, 21(6): 920-923, 957. doi: 10.16766/j.cnki.issn.1674-4152.003015
    [5]
    HAN S W, DENG Z J, CHEUNG K S, et al. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol[J]. BMC Gastroenterol, 2023, 23(1): 231. doi: 10.1186/s12876-023-02872-7
    [6]
    FERRARI F, OGATA D C, MELLO C A L. Role of incisura angularis biopsy in gastritis staging and risk assessment of gastric cancer[J]. Arq Gastroenterol, 2023, 60(4): 478-489. doi: 10.1590/s0004-2803.23042023-120
    [7]
    崔艳艳, 柯希权, 王启之, 等. 安徽省皖北地区120例消化道疾病患者幽门螺杆菌耐药性研究[J]. 中华全科医学, 2022, 20(11): 1852-1855. doi: 10.16766/j.cnki.issn.1674-4152.002718

    CUI Y Y, KE X Q, WANG Q Z, et al. Drug resistance of Helicobacter pylori in 120 patients with digestive tract diseases in Northern Anhui Province[J]. Chinese Journal of General Practice, 2022, 20(11): 1852-1855. doi: 10.16766/j.cnki.issn.1674-4152.002718
    [8]
    MIAO J, HU C, TANG J, et al. Pharmacokinetics, safety, and tolerability of vonoprazan- or esomeprazole-based bismuth-containing quadruple therapy: a phase 1, double-blind, parallel-group study in adults with Helicobacter pylori infection in China[J]. Clin Pharmacol Drug Dev, 2023, 12(10): 1036-1044. doi: 10.1002/cpdd.1276
    [9]
    ZHOU S F, XIE L J, ZHOU C, et al. Keverprazan, a novel potassium-competitive acid blocker: multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects[J]. Clin Transl Sci, 2023, 16(10): 1911-1922. doi: 10.1111/cts.13598
    [10]
    DU R C, HU Y X, OUYANG Y B, et al. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: a systematic review and meta-analysis[J]. Helicobacter, 2024, 29(1): e13039. DOI: 10.1111/hel.13039.
    [11]
    HAN Y Y, ZHOU L, HU Y L, et al. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study[J]. J Gastroenterol, 2023, 58(12): 1167-1177. doi: 10.1007/s00535-023-02042-2
    [12]
    LU F F, XU W T, SHI X Y, et al. 14-day vonoprazan-based bismuth quadruple therapy for treatment-naïve patients with Helicobacter pylori infection: a retrospective comparative study[J]. Int J Gen Med, 2023, 16: 4279-4281. doi: 10.2147/IJGM.S427450
    [13]
    HU Y, XU X, LIU X S, et al. Fourteen-day vonoprazan and low-or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: a prospective, open-labeled, randomized non-inferiority clinical study[J]. Front Immunol, 2023, 13: 1049908. DOI: 10.3389/fimmu.2022.1049908.
    [14]
    张国新, 钱海声. 伏诺拉生用于幽门螺杆菌根除的研究进展[J]. 中国实用内科杂志, 2023, 43(4): 277-281. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK202304004.htm

    ZHANG G X, QIAN H S. Research progress of Vonoprazan in eradication of Helicobacter pylori[J]. Chinese Journal of Practical Internal Medicine, 2023, 43(4): 277-281. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK202304004.htm
    [15]
    OH C K, LIM H, SEO S I, et al. Efficacy comparison of 7-and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial[J]. BMC Gastroenterol, 2023, 23(1): 453. doi: 10.1186/s12876-023-03100-y
    [16]
    许文涛, 许向波, 任天舒, 等. 伏诺拉生在幽门螺杆菌根除治疗中的作用研究进展[J]. 解放军医学杂志, 2022, 47(9): 947-953. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJY202209011.htm

    XU W T, XU X B, REN T S, et al. Research advances on vonoprazan for eradication of Helicobacter pylori[J]. Medical Journal of Chinese People ' s Liberation Army, 2022, 47(9): 947-953. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJY202209011.htm
    [17]
    LI J, LV L, ZHU Y J, et al. A modified 14-day dual therapy with vonoprazan and amoxicillin amplified the advantages over conventional therapies for eradication of Helicobacter pylori: a non-inferiority clinical trial[J]. Infect Drug Resist, 2023, 16: 5637-5645. doi: 10.2147/IDR.S417711
    [18]
    罗江钊. 适用于肠易激综合征的酵母益生菌[J]. 中国食品学报, 2022, 22(10): 458. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSP202210046.htm

    LUO J Z. Yeast probiotics for irritable bowel syndrome[J]. Journal of Chinese Institute of Food Science and Technology, 2022, 22(10): 458. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSP202210046.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (98) PDF downloads(5) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return